Pulmatrix Receives European Patent for Its Inhaled Drug Delivery Technology
PRNewswire: March 21, 2017 – LEXINGTON, MA, U.S.A. – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key patent from the European Union.
“This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery,” said Robert W. Clarke, Ph.D., chief executive officer for Pulmatrix. “It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates for COPD, fungal infections, and other diseases.”
The new EU patent (EP 2410981 B1) follows on similar patents that Pulmatrix has been granted in the United States and Japan. The most important of those patents is U.S. 9,433,576, which gives broad protection to Pulmatrix’s innovative drug delivery technology— and to its use to treat a wide variety of diseases.
These patents explain that delivering drugs directly to the lungs offers numerous advantages. But the full potential can’t be realized unless most of the drug actually gets to the lungs, rather than being stuck in the throat or mouth, causing side effects. Pulmatrix’s technology uses dry powders that “fly” easily into the lungs, making the delivery much more efficient. In addition, the technology can deliver much larger doses of drugs—and many more different types of drugs—than existing methods can.
“This new patent means that we are now protected from competitors copying our advances in Europe, as well as in the United States,” added Dr. Clarke.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The company’s proprietary product pipeline is focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD), and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare disease like cystic fibrosis. Pulmatrix’s product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
